A case of insulinoma with hypoglycemia that was better managed with lanreotide than octreotide
Abstract Long‐acting somatostatin analogs, including lanreotide slow release (LAN‐SR) and octreotide long‐acting release (OCT‐LAR), can improve hypoglycemia in insulinoma. LAN‐SR may be more beneficial in some patients with insulinoma than OCT‐LAR.
Main Authors: | Keiko Yamaoka, Shuichi Nagashima, Nobukazu Okada, Nagisa Sawayama, Shinsuke Saito, Manabu Takahashi, Kenta Okada, Kazuhiro Endo, Masaru Koizumi, Hideki Sasanuma, Ken Ebihara, Atsuko Kasajima, Noriyoshi Fukushima, Naohiro Sata, Shun Ishibashi |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-05-01
|
Series: | Clinical Case Reports |
Subjects: | |
Online Access: | https://doi.org/10.1002/ccr3.4118 |
Similar Items
-
Lanreotide for the treatment of patients with disseminated high-grade neuroendocrine tumors: the experience of application in case of unsatisfactory tolerability of octreotide
by: G S Emelyanova, et al.
Published: (2016-03-01) -
Treatment with Lanreotide Depot Following Octreotide Long-Acting Release Among Patients with Gastroenteropancreatic Neuroendocrine Tumors
by: Muhammad Wasif Saif, et al.
Published: (2018-10-01) -
A case of malignant insulinoma responsive to somatostatin analogs treatment
by: Mariasmeralda Caliri, et al.
Published: (2018-12-01) -
Adherence to somatostatin analog therapy for acromegaly
by: I. A. Ilovayskaya
Published: (2021-05-01) -
Long-term Primary Medical Therapy with Somatostatin Analogs in Acromegaly
by: Deng-Huang Su
Published: (2006-01-01)